The relationship between the efficacy and the prevalence of the mutant virus for the novel anti-viral drugs for hepatitis C

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460994
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Osaka University
• Principal Investigator: hiramatsu naoki 大阪大学, 医学(系)研究科(研究院), 准教授 (30362700)
• Co-Investigator(Kenkyū-buntansha): OZE tsugiko 大阪大学, 大学院医学系研究科, 寄附講座助教 (30623582)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 薬剤耐性変異 / C型肝炎 / DAA治療

Outline of Final Research Achievements

Factors associated with the treatment effect,including RAVs in the NS3 region, were examined in 21 patients with genotype 1b HCV infection who were treated with SMV-based therapy after failure of TVR-based therapy.
The SVR rate was 50% (10/20,PPS).Ultra-deep sequencing at the start of SMV-based therapy revealed that TVR-resistant variants were detected in 6 patients (29%),and no variants at position 168 were observed. Cross-resistant variants between TVR and SMV were detected in only one patient(SVR).Higher SVRs for SMV-based therapy were attained in relapsers to prior Peg-IFN plus RBV therapy (relapsers 100% vs non-responders 20%, p = 0.007).
In this study, ultra-deep sequencing analysis revealed that TVR and/or SMV-resistant variants may have no influence on the effect of SMV-based therapy after failure of TVR-based therapy. Relapsers to previous Peg-IFN/RBV therapy would be a good candidate for retreatment with SMV-based triple therapy.

Free Research Field

C型肝炎